SHILPA MEDICARE Latest Share Price (SHILPAMED)
TODAY IN ONE LINE
SHILPAMED rose 2.3% on above-average volume (1.5x avg), outperforming Nifty's -0.3% move, reaching near its 52-week high of ₹980.1.
With a market cap of ₹18,834.53 Cr., it trades at a P/E of 63.36. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
SHILPA MEDICARE flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 644.6% YoY
- ●Healthy Operating MarginsOPM is structurally strong at 26.5%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.05x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 59.4% YoY
- ●Poor Capital ReturnsLow ROE of 4.9%
- ●Rising Receivables vs SalesReceivables grew 21.1% outpacing sales growth of 11.7%
Latest SHILPA MEDICARE News
What changed recently?
Recent events, corporate actions, and announcements.
SHILPA MEDICARE valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for SHILPA MEDICARE, framed against the sector median so the premium or discount is obvious at a glance.
SHILPA MEDICARE trades at a P/E of 63.36× and P/B of 7.27×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
SHILPA MEDICARE technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SHILPA MEDICARE — derived from the latest tape, not yesterday's close.
SHILPA MEDICARE last traded at ₹961.15 with an intraday range of ₹910–₹975 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹961.15| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1117.43 | +156.28 | +16.26% |
| R3 | 1052.43 | +91.28 | +9.50% |
| R2 | 1013.72 | +52.57 | +5.47% |
| R1 | 987.43 | +26.28 | +2.73% |
| PIVOT | 948.72 | -12.43 | -1.29% |
| CURRENT | 961.15 | — | — |
| S1 | 922.43 | -38.72 | -4.03% |
| S2 | 883.72 | -77.43 | -8.06% |
| S3 | 857.43 | -103.72 | -10.79% |
| S4 | 792.43 | -168.72 | -17.55% |
SHILPAMED is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹910–₹939
Trading Inside opening range
SHILPA MEDICARE financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for SHILPA MEDICARE — consolidated or standalone — with margins, YoY growth and key ratios inline.
SHILPA MEDICARE reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹18,834.53 Cr. and reported EPS of ₹3.32.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,286 | 1,539 ▲ 19.6% |
| Sales Growth YoY %Derived | 11.71% | 19.62% |
| Other Income | 23 | 10 ▼ 57.5% |
| Total Income | 1,310 | 1,549 ▲ 18.3% |
| 410 | 460 ▲ 12.2% | |
| Gross ProfitDerived | 876 | 1,078 ▲ 23.1% |
| Gross Margin %Derived | 68.10% | 70.08% |
| 559 | 644 ▲ 15.2% | |
| EBITDA (Operating Profit)Derived | 317 | 435 ▲ 37.1% |
| OPM %Derived | 24.65% | 28.25% |
| 160 | 208 ▲ 29.5% | |
| Profit Before Tax (PBT) | 124 | 295 ▲ 138.9% |
| 44 | 52 ▲ 18.0% | |
| Effective Tax %Derived | 35.63% | 17.60% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 78 | 243 ▲ 210.8% |
| Less: Non-controlling Interests | -0 | — ▲ 100.0% |
| Net Profit (Owner's PAT)Derived | 78 | 243 ▲ 210.8% |
| Net Profit Margin %Derived | 6.09% | 15.81% |
| PAT Growth YoY %Derived | 145.64% | 210.78% |
| Earnings Per Share (EPS ₹) | 4.00 | 12.44 ▲ 211.0% |
| Diluted Shares Outstanding (Cr) | 20 | 20 ▲ 0.0% |
| Share of Profit from Associates/JVs | -1 | — ▲ 100.0% |
| Other Comprehensive Income (Net of Tax) | -2 | — ▲ 100.0% |
| Total Expenses (incl. D&A & Interest) | 1,186 | 1,253 ▲ 5.7% |
| Material Cost % of RevenueDerived | 27.23% | 30.61% |
| Employee Cost % of RevenueDerived | 22.75% | 21.76% |
| Other Cost % of RevenueDerived | 20.70% | 20.07% |
| Interest Coverage (x)Derived | 2.70x | 5.36x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 792 | 733 ▼ 7.3% | 908 ▲ 23.8% | 901 ▼ 0.7% | 1,146 ▲ 27.1% | 1,050 ▼ 8.3% | 1,152 ▲ 9.7% | 1,286 ▲ 11.7% | 1,539 ▲ 19.6% | |
| Sales Growth YoY %Derived | — | -7.35% | 23.80% | -0.75% | 27.12% | -8.33% | 9.66% | 11.71% | 19.62% | |
| Other Income | 22 | 14 ▼ 36.6% | 17 ▲ 23.3% | 30 ▲ 77.9% | 14 ▼ 52.7% | 17 ▲ 22.1% | 8 ▼ 53.0% | 23 ▲ 183.4% | 10 ▼ 57.5% | |
| Total Income | 813 | 747 ▼ 8.1% | 925 ▲ 23.8% | 931 ▲ 0.7% | 1,160 ▲ 24.5% | 1,068 ▼ 8.0% | 1,160 ▲ 8.6% | 1,310 ▲ 12.9% | 1,549 ▲ 18.3% | |
356 | 257 ▼ 27.9% | 278 ▲ 8.2% | 271 ▼ 2.5% | 383 ▲ 41.5% | 416 ▲ 8.5% | 408 ▼ 2.0% | 410 ▲ 0.7% | 460 ▲ 12.2% | ||
| Gross ProfitDerived | 436 | 477 ▲ 9.4% | 630 ▲ 32.2% | 630 ▲ 0.0% | 762 ▲ 20.9% | 634 ▼ 16.8% | 744 ▲ 17.3% | 876 ▲ 17.7% | 1,078 ▲ 23.1% | |
| Gross Margin %Derived | 55.04% | 65.02% | 69.41% | 69.96% | 66.55% | 60.39% | 64.61% | 68.10% | 70.08% | |
273 | 321 ▲ 17.4% | 410 ▲ 27.8% | 449 ▲ 9.3% | 558 ▲ 24.4% | 532 ▼ 4.8% | 500 ▼ 6.1% | 559 ▲ 11.9% | 644 ▲ 15.2% | ||
| EBITDA (Operating Profit)Derived | 162 | 156 ▼ 3.9% | 220 ▲ 41.1% | 182 ▼ 17.4% | 204 ▲ 12.2% | 102 ▼ 49.8% | 244 ▲ 139.0% | 317 ▲ 29.7% | 435 ▲ 37.1% | |
| OPM %Derived | 20.49% | 21.25% | 24.21% | 20.16% | 17.80% | 9.74% | 21.23% | 24.65% | 28.25% | |
40 | 66 ▲ 64.5% | 48 ▼ 26.9% | 135 ▲ 181.2% | 126 ▼ 6.6% | 154 ▲ 22.2% | 206 ▲ 33.5% | 160 ▼ 22.0% | 208 ▲ 29.5% | ||
| Profit Before Tax (PBT) | 144 | 144 ▼ 0.2% | 188 ▲ 30.9% | 195 ▲ 3.7% | 102 ▼ 47.6% | -34 ▼ 133.7% | 59 ▲ 271.5% | 124 ▲ 109.1% | 295 ▲ 138.9% | |
34 | 26 ▼ 22.8% | 33 ▲ 27.9% | 49 ▲ 45.9% | 42 ▼ 14.7% | -7 ▼ 117.7% | 22 ▲ 404.0% | 44 ▲ 96.7% | 52 ▲ 18.0% | ||
| Effective Tax %Derived | 23.55% | 18.22% | 17.81% | 25.04% | 40.76% | 21.36% | 37.87% | 35.63% | 17.60% | |
| Profit/Loss from Discontinued Ops | — | — | — | 2 | 0 ▼ 94.9% | — ▼ 100.0% | — | — | — | |
| Total Profit for Period | 103 | 110 ▲ 6.5% | 156 ▲ 42.6% | 146 ▼ 6.4% | 61 ▼ 58.6% | -32 ▼ 153.6% | 32 ▲ 198.1% | 78 ▲ 145.6% | 243 ▲ 210.8% | |
| Less: Non-controlling Interests | -2 | -3 ▼ 16.0% | — ▲ 100.0% | — | — | — | — | -0 | — ▲ 100.0% | |
| Net Profit (Owner's PAT)Derived | 105 | 112 ▲ 6.7% | 156 ▲ 39.1% | 146 ▼ 6.4% | 61 ▼ 58.6% | -32 ▼ 153.6% | 32 ▲ 198.1% | 78 ▲ 145.6% | 243 ▲ 210.8% | |
| Net Profit Margin %Derived | 13.30% | 15.31% | 17.20% | 16.22% | 5.29% | -3.09% | 2.77% | 6.09% | 15.81% | |
| PAT Growth YoY %Derived | — | 6.67% | 39.10% | -6.37% | -58.56% | -153.61% | 198.15% | 145.64% | 210.78% | |
| Earnings Per Share (EPS ₹) | 6.45 | 6.88 ▲ 6.7% | 9.58 ▲ 39.2% | 9.06 ▼ 5.4% | 3.49 ▼ 61.5% | -1.87 ▼ 153.6% | 1.84 ▲ 198.4% | 4.00 ▲ 117.4% | 12.44 ▲ 211.0% | |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 17 ▲ 6.5% | 17 ▲ 0.0% | 17 ▲ 0.0% | 20 ▲ 12.7% | 20 ▲ 0.0% | |
| Share of Profit from Associates/JVs | -7 | -8 ▼ 11.5% | 2 ▲ 119.9% | — ▼ 100.0% | — | -5 | -5 ▲ 9.5% | -1 ▲ 74.0% | — ▲ 100.0% | |
| Other Comprehensive Income (Net of Tax) | 1 | 0 ▼ 60.7% | -1 ▼ 342.7% | 0 ▲ 125.9% | -1 ▼ 603.6% | 3 ▲ 336.7% | -2 ▼ 173.5% | -2 ▲ 2.9% | — ▲ 100.0% | |
| Total Expenses (incl. D&A & Interest) | 669 | 603 ▼ 9.8% | 737 ▲ 22.1% | 736 ▼ 0.1% | 1,058 ▲ 43.6% | 1,102 ▲ 4.2% | 1,101 ▼ 0.1% | 1,186 ▲ 7.8% | 1,253 ▲ 5.7% | |
| Material Cost % of RevenueDerived | 38.91% | 33.97% | 31.61% | 35.39% | 33.33% | 35.12% | 36.85% | 27.23% | 30.61% | |
| Employee Cost % of RevenueDerived | 18.84% | 24.05% | 21.65% | 26.11% | 23.09% | 27.36% | 24.44% | 22.75% | 21.76% | |
| Other Cost % of RevenueDerived | 15.71% | 19.72% | 23.55% | 23.69% | 25.66% | 23.29% | 18.94% | 20.70% | 20.07% | |
| Interest Coverage (x)Derived | 46.95x | 30.95x | 38.62x | 5.84x | 3.01x | 0.12x | 1.49x | 2.70x | 5.36x |
SHILPA MEDICARE segment analysis : revenue and profit mix.
Disclosed business segments at SHILPA MEDICARE with their share of revenue and profit, switchable between consolidated and standalone reporting.
SHILPA MEDICARE discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for SHILPA MEDICARE.
Our AI distills the core fundamental drivers supporting SHILPA MEDICARE, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
SHILPA MEDICARE's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 82 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.09%.
SHILPA MEDICARE peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SHILPA MEDICARE is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
SHILPA MEDICARE chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for SHILPA MEDICARE — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
SHILPA MEDICARE delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for SHILPA MEDICARE over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in SHILPA MEDICARE stood at 26.1% of traded volume, against a 20-day average of 41.5%.
SHILPA MEDICARE announcements: results, concalls, ratings, M&A.
Filings SHILPA MEDICARE sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
SHILPA MEDICARE files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 168 documents below.
Shareholders meeting
Shilpa Medicare Limited has informed the Exchange regarding voting results of Annual General Meeting held on September 11, 2026
Press Release
Shilpa Medicare Limited has informed the Exchange regarding a press release dated September 11, 2026, titled "Shilpa Medicare's Novel Complex…
Shareholders meeting
Shilpa Medicare Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 11, 2026
Action(s) initiated or orders passed
Shilpa Medicare Limited has informed the Exchange about Action(s) initiated or orders passed
General Updates
Dispatch of letter to shareholders whose e-mail addresses are not registered with Company/Registrar & Transfer Agent/Depository Participants.
Investor decks & rating reports.
SHILPA MEDICARE dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue SHILPA MEDICARE has declared, sequenced by announce and record date.
SHILPA MEDICARE corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About SHILPA MEDICARE: business, sector, key facts.
What SHILPA MEDICARE does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
SHILPA MEDICARE operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: SHILPAMED, BSE: 530549.
Shilpa Medicare Limited is a pharmaceutical company headquartered in Raichur, India, with a global reach encompassing the United States and Europe. The company's core business is the manufacture and sale of active pharmaceutical ingredients (APIs) and finished dosage formulations. Their extensive API portfolio caters to both oncology and non-oncology treatments, including a wide range of molecules like anastrozole, azacitidine, bortezomib, capecitabine, dasatinib, and many others, showcasing their capabilities in producing complex and specialized chemical compounds. They also offer a significant array of intermediates, high-purity peptides, specialty and biopolymers, and biologics.
Beyond APIs, Shilpa Medicare's capabilities extend to the manufacturing of diverse finished dosage formulations. These include a variety of delivery systems such as tablets, capsules, liquid and dry powder injections, orally disintegrating films, transdermal patches, and lyophilized injectables. Their specialization in oncology formulations highlights a key area of focus within their product offerings. This broad range of formulations caters to different patient needs and administration preferences, showcasing a commitment to diverse pharmaceutical delivery methods.
The company provides contract development and manufacturing services (CDMO), indicating a willingness to partner with other pharmaceutical companies to produce their products. This aspect of their business demonstrates a capacity to leverage their expertise and manufacturing infrastructure to support other players in the industry. Additionally, Shilpa Medicare is involved in wind power generation, indicating diversification beyond their core pharmaceutical operations.
In summary, Shilpa Medicare's business model combines the manufacturing and sale of a vast array of APIs and finished dosage formulations, with a focus on oncology treatments, complemented by CDMO services and diversification into renewable energy. This multifaceted approach establishes a robust and diverse pharmaceutical and energy company with a strong international presence.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about SHILPA MEDICARE (SHILPAMED).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of SHILPA MEDICARE (SHILPAMED)?
The current share price of SHILPA MEDICARE (SHILPAMED) is ₹961.15. Today, the stock has gained by ₹21.25 (2.26%), trading in a range of ₹910.00 to ₹975.00. The stock opened at ₹935.00 with a trading volume of 14,71,659 shares.
02Is SHILPA MEDICARE stock a good investment for long-term?
SHILPA MEDICARE can be considered for long-term investment based on several factors. The company has a market capitalization of ₹18,834.53 Cr., P/E ratio of 63.36, ROE of 4.9%, and ROCE of 5.01%. The dividend yield stands at 0.17%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of SHILPA MEDICARE stock?
The 52-week high price of SHILPA MEDICARE (SHILPAMED) is ₹980.10, while the 52-week low is ₹259.50. Currently trading at ₹961.15, the stock is 270.39% above its 52-week low and 1.93% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy SHILPA MEDICARE stock at the current price?
Whether to buy SHILPA MEDICARE stock at ₹961.15 depends on multiple factors. The stock is currently trading with a P/E ratio of 63.36 and P/B ratio of 7.27. Today's performance shows a gain of 2.26%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of SHILPA MEDICARE and when is the next dividend?
SHILPA MEDICARE offers a dividend yield of 0.17%, which means for every ₹100 invested at the current price of ₹961.15, you can expect to receive approximately ₹0.17 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of SHILPA MEDICARE?
SHILPA MEDICARE's key financial metrics include: P/E Ratio: 63.36, P/B Ratio: 7.27, ROE: 4.9%, ROCE: 5.01%, Dividend Yield: 0.17%, EPS: ₹3.32, Book Value: ₹132.49, and Debt-to-Equity: 0.05. The company's market cap stands at ₹18,834.53 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is SHILPA MEDICARE stock performing today in the market?
SHILPA MEDICARE stock opened at ₹935.00 and is currently trading at ₹961.15, showing a gain of ₹21.25 (2.26%). The intraday high is ₹975.00 and low is ₹910.00. The trading volume stands at 14,71,659 shares, indicating strong market participation today.
08What is the P/E ratio of SHILPA MEDICARE and what does it indicate?
SHILPA MEDICARE has a Price-to-Earnings (P/E) ratio of 63.36, which means investors are willing to pay 63.36 for every ₹1 of earnings. With an EPS of ₹3.32, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about SHILPA MEDICARE (SHILPAMED) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.